Royalty Pharma plc (RPRX)

Royalty Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	2,355	2,237	2,289	2,122	1,814
Revenue Growth (YoY)	5.24%	-2.28%	7.87%	16.98%	1.08%
Gross Profit	2,355	2,237	2,289	2,122	1,814
Selling, General & Admin	249.75	227.3	182.83	181.72	103.44
Research & Development	52	177.11	200.08	26.29	83.04
Other Operating Expenses	560.66	1,526	475.84	318.95	-995.4
Operating Expenses	862.4	1,930	858.75	526.95	-808.92
Operating Income	1,492	307.07	1,431	1,595	2,623
Interest Expense / Income	187.19	187.96	166.14	157.06	268.57
Other Expense / Income	170.13	76.27	644.85	463.3	6.07
Pretax Income	1,135	42.83	619.73	975.04	2,349
Net Income	1,135	42.83	619.73	975.04	2,349
Net Income Growth	2549.50%	-93.09%	-36.44%	-58.48%	70.46%
Shares Outstanding (Basic)	448	438	415	375	595
Shares Outstanding (Diluted)	603	438	415	375	-
Shares Change	37.66%	5.59%	10.48%	-36.94%	-
EPS (Basic)	2.54	0.10	1.49	1.32	-
EPS (Diluted)	2.53	0.10	1.49	1.32	-
EPS Growth	2430.00%	-93.29%	12.88%	-	-
Free Cash Flow	2,975	2,144	1,999	2,035	1,417
Free Cash Flow Per Share	6.65	4.89	4.82	5.42	2.38
Dividend Per Share	0.800	0.760	0.680	0.300	-
Dividend Growth	5.26%	11.76%	126.67%	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	63.37%	13.73%	62.49%	75.17%	144.59%
Profit Margin	48.20%	1.91%	27.07%	45.94%	129.45%
Free Cash Flow Margin	126.37%	95.83%	87.31%	95.87%	78.12%
EBITDA	1,322	230.79	785.87	1,132	2,617
EBITDA Margin	56.15%	10.32%	34.33%	53.34%	144.25%
EBIT	1,322	230.79	785.87	1,132	2,617
EBIT Margin	56.15%	10.32%	34.33%	53.34%	144.25%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).